Galapagos NV (NASDAQ:GLPG)‘s stock had its “buy” rating reissued by research analysts at BTIG Research in a research note issued on Monday. They currently have a $118.00 price objective on the biotechnology company’s stock. BTIG Research’s price objective would suggest a potential upside of 26.35% from the company’s current price.

Several other research analysts have also recently issued reports on the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $120.00 price objective on shares of Galapagos NV in a research report on Sunday, October 29th. Zacks Investment Research raised Galapagos NV from a “sell” rating to a “hold” rating in a research report on Wednesday, October 11th. Morgan Stanley reissued an “overweight” rating and issued a $123.00 target price (up from $92.00) on shares of Galapagos NV in a research report on Friday, October 6th. Royal Bank Of Canada began coverage on Galapagos NV in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $98.00 target price for the company. Finally, BidaskClub raised Galapagos NV from a “sell” rating to a “hold” rating in a research report on Thursday, August 17th. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $111.00.

Galapagos NV (GLPG) traded up $2.56 during trading hours on Monday, hitting $93.39. The stock had a trading volume of 121,500 shares, compared to its average volume of 153,645. Galapagos NV has a twelve month low of $57.16 and a twelve month high of $104.12.

ILLEGAL ACTIVITY NOTICE: “Galapagos NV (GLPG) Receives “Buy” Rating from BTIG Research” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/21/galapagos-nv-glpg-receives-buy-rating-from-btig-research.html.

Hedge funds have recently modified their holdings of the company. Advisors Preferred LLC purchased a new position in shares of Galapagos NV during the 3rd quarter worth approximately $105,000. Envestnet Asset Management Inc. raised its stake in shares of Galapagos NV by 156.6% during the 3rd quarter. Envestnet Asset Management Inc. now owns 1,742 shares of the biotechnology company’s stock worth $177,000 after buying an additional 1,063 shares in the last quarter. Tower Research Capital LLC TRC purchased a new position in shares of Galapagos NV during the 1st quarter worth approximately $161,000. Bank of Montreal Can raised its stake in shares of Galapagos NV by 8,736.4% during the 1st quarter. Bank of Montreal Can now owns 1,944 shares of the biotechnology company’s stock worth $168,000 after buying an additional 1,922 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new position in shares of Galapagos NV during the 3rd quarter worth approximately $218,000. 21.42% of the stock is owned by institutional investors and hedge funds.

About Galapagos NV

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Analyst Recommendations for Galapagos NV (NASDAQ:GLPG)

Receive News & Ratings for Galapagos NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos NV and related companies with MarketBeat.com's FREE daily email newsletter.